

It is illegal to post this copyrighted PDF on any website.

Lurasidone Dose Escalation in Early Nonresponding Patients With Schizophrenia: A Randomized, Placebo-Controlled Study

Antony Loebel, MD^{a,*}; Robert Silva, PhD^a; Robert Goldman, PhD^a; Kei Watabe, MS^a; Josephine Cucchiaro, PhD^a; Leslie Citrome, MD, MPH^b; and John M. Kane, MD^c

ABSTRACT

Objective: To assess the effect of dose increase in adult patients with schizophrenia who demonstrate inadequate initial response to standard-dose lurasidone and to evaluate the efficacy of low-dose lurasidone in adult patients with schizophrenia.

Methods: In this randomized, double-blind, placebo-controlled study conducted between May 2013 and June 2014, hospitalized patients with acute schizophrenia (*DSM-IV-TR* criteria) were randomly assigned to double-blind treatment with lurasidone 20 mg/d (n = 101), lurasidone 80 mg/d (n = 199), or placebo (n = 112). Nonresponders to lurasidone 80 mg/d (Positive and Negative Syndrome Scale [PANSS] score decrease < 20%) at 2 weeks were re-randomized to lurasidone 80 mg/d or 160 mg/d for the remaining 4 weeks of the study. The primary outcome measure was change from baseline to week 6 in PANSS total score.

Results: In nonresponders to lurasidone 80 mg/d (n = 95), dose increase to 160 mg/d at week 2 significantly reduced PANSS total score at week 6 study endpoint compared with continuing 80 mg/d (-16.6 vs -8.9; *P* < .05 [effect size = 0.52]). While a comparable magnitude of improvement was observed in Clinical Global Impression-Severity (CGI-S) score from week 2 to week 6 endpoint for lurasidone 160 mg/d versus 80 mg/d (-1.0 vs -0.6; effect size = 0.44), the difference was not statistically significant (*P* = .052). Patients receiving lurasidone 20 mg/d did not demonstrate significant improvement compared with placebo at week 6 in PANSS total (-17.6 vs -14.5; *P* = .26) or CGI-S (-0.93 vs -0.73; *P* = .17) scores. Few dose-related adverse effects associated with lurasidone were observed.

Conclusions: In adult patients with schizophrenia demonstrating nonresponse to 2 weeks of treatment with lurasidone 80 mg/d, dose increase to 160 mg/d resulted in significant symptom improvement compared with continuing lurasidone 80 mg/d. Lurasidone 20 mg/d was not associated with significant improvement in psychotic symptoms in adult patients with schizophrenia.

Trial Registration: ClinicalTrials.gov identifier: NCT01821378

J Clin Psychiatry 2016;77(12):1672–1680

dx.doi.org/10.4088/JCP.16m10698

© Copyright 2016 Physicians Postgraduate Press, Inc.

^aSunovion Pharmaceuticals Inc, Fort Lee, New Jersey, and Marlborough, Massachusetts

^bDepartment of Psychiatry & Behavioral Sciences, New York Medical College, Valhalla

^cDepartment of Psychiatry, The Zucker Hillside Hospital, Glen Oaks; and Department of Psychiatry, Hofstra North Shore-Long Island Jewish School of Medicine, Hempstead, New York

*Corresponding author: Antony Loebel, MD, Sunovion Pharmaceuticals Inc, One Bridge Plaza North, Ste 510, Fort Lee, NJ 07024 (antony.loebel@sunovion.com).

Lack of adequate improvement early in the course of antipsychotic therapy has been established as a predictor of later nonresponse in multiple short-term studies of patients with acute schizophrenia.^{1–10} Strategies for addressing early nonresponse have not been well studied, however, resulting in little empirical evidence to inform clinical decision-making for patients with schizophrenia who demonstrate an inadequate initial response to treatment. Potential management strategies for early nonresponse include continuation of the initial treatment (ie, waiting for further improvement), dose escalation, augmentation with adjunctive treatments, or a switch to another antipsychotic medication.^{11,12}

Lurasidone is an atypical antipsychotic agent with high binding affinity for D₂, 5-HT_{2A}, and 5-HT₇ receptors (antagonist), moderate affinity for 5-HT_{1A} receptors (partial agonist), and no appreciable affinity for H₁ and M₁ receptors.¹³ Lurasidone was approved for the treatment of adult patients with schizophrenia based on 5 short-term, placebo-controlled studies that evaluated the dose range of 40–160 mg/d.^{14–18} The current study had 2 main objectives: to evaluate the efficacy of lurasidone dose increase in patients with an inadequate response after 2 weeks of standard-dose lurasidone therapy and to determine the potential efficacy of low-dose lurasidone (20 mg/d) in patients with schizophrenia.

METHODS

Patients

This study enrolled patients 18–75 years of age diagnosed with schizophrenia for ≥ 6 months (*DSM-IV-TR* criteria) and experiencing an acute exacerbation (< 2 months in duration), as indicated by a PANSS total score ≥ 80; a PANSS item score ≥ 4 (moderate) on ≥ 2 of the following items: delusions, conceptual disorganization, hallucinations, and unusual thought content; and a Clinical Global Impression-Severity (CGI-S) score ≥ 4 (moderately ill). Patients were excluded if another *DSM-IV* diagnosis had been the primary focus of treatment within the previous 3 months or if they had a history of alcohol or substance abuse (previous 3 months), showed evidence of a severe movement disorder, or were considered by the investigator to be at imminent risk of suicide or injury to self or others.

The study was approved by an institutional review board or ethics committee at each investigational site and was conducted in accordance with the International Conference on

It is illegal to post this copyrighted PDF on any website.

- Limited evidence is available to guide clinicians in selecting appropriate treatment strategies for patients with schizophrenia who demonstrate early nonresponse to antipsychotic therapy.
- This study provides controlled evidence that early nonresponders with schizophrenia may benefit from an increase in lurasidone dose from 80 mg/d to 160 mg/d. Significantly greater improvement in schizophrenia symptoms was found after lurasidone dose escalation compared with continuing the initial dose.
- Lurasidone 20 mg/d was not efficacious for the treatment of adult patients with acute schizophrenia.

Harmonization Good Clinical Practices guidelines and with the ethical principles of the Declaration of Helsinki. After complete description of the study to the patients, written informed consent was obtained. The study was registered at ClinicalTrials.gov (identifier: NCT01821378).

Study Design

This multiregional, 6-week, randomized, double-blind, placebo-controlled, parallel-group study was conducted between May 2013 and June 2014. The rationale and design of this study are discussed in greater detail in a separate report.¹⁹

A total of 412 patients underwent random assignment in a 1:2:1 ratio via an interactive voice/web response system to receive fixed-dose lurasidone 20 mg/d, lurasidone 80 mg/d, or placebo. Study medication was provided in blister packs of identically matched lurasidone 20 mg, lurasidone 40 mg, or placebo tablets. A central randomization center used a computer-generated list of random numbers to allocate study treatments. None of the investigators, study staff, or patients had access to randomization codes or list. Study medication was taken in the evening with a meal or within 30 minutes after eating. Patients assigned to lurasidone 20 mg/d or placebo received the same medication throughout the study. Patients assigned to lurasidone 80 mg/d received this dose for the first 2 weeks, at which time they were classified as early responders ($\geq 20\%$ improvement from baseline in PANSS total score) or early nonresponders ($< 20\%$ improvement). Early responders continued to take lurasidone 80 mg/d, while early nonresponders were re-randomized in a 1:1 ratio either to continue lurasidone 80 mg/d or to receive 160 mg/d for the remaining 4 weeks of the study. Exposure to lurasidone was evaluated using pharmacokinetic analysis of blood samples taken at weeks 2, 4, and 6.

Hospitalization was mandatory for all patients through week 3, after which patients deemed clinically stable and appropriate for discharge (including CGI-S score ≤ 3) were followed as outpatients.

Concomitant Medications

Treatment with anticholinergic agents or propranolol was permitted for movement disorders as needed (but not prophylactically). Lorazepam, temazepam, and zolpidem

(or their equivalents) were permitted as needed for anxiety or insomnia but not within 8 hours of any psychiatric assessment.

Efficacy Assessments

Efficacy and safety assessments were performed by qualified site-based raters. The primary and key secondary efficacy endpoints were the change from baseline to week 6 in PANSS total score and CGI-S score, respectively, for the lurasidone 20 mg/d group compared with the placebo group. Secondary efficacy endpoints included change from baseline to week 6 on the PANSS and CGI-S for patients randomized to 80 mg/d compared with the placebo group and change from week 2 to week 6 for early nonresponders who received lurasidone 160 mg/d versus 80 mg/d.

Safety and Tolerability Evaluation

Safety and tolerability were assessed by the incidence and severity of adverse events during the study. Movement disorders were assessed by the Simpson-Angus Scale, the Barnes Akathisia Rating Scale, and the Abnormal Involuntary Movement Scale. Additional safety evaluations included vital signs, laboratory tests, 12-lead electrocardiogram (ECG), and physical examination. Suicidal ideation and behavior were assessed using the Columbia-Suicide Severity Rating Scale (C-SSRS).


Statistical Analysis

The intent-to-treat (ITT) population consisted of randomly assigned patients who received at least 1 dose of study medication and had a least 1 postbaseline efficacy assessment. The early nonresponder (ENR) ITT population consisted of patients in the lurasidone 80 mg/d group who were re-randomized at week 2 (to lurasidone 80 mg/d or 160 mg/d), received at least 1 dose of study medication after randomization, and had at least 1 subsequent efficacy assessment. For early nonresponders who continued on lurasidone 80 mg/d (ENR 80 mg) or increased to 160 mg/d (ENR 160 mg), efficacy results are presented from week 2 (time of re-randomization) to week 6. Efficacy endpoints were evaluated using a mixed model for repeated measures (MMRM) analysis that included treatment, visit, pooled center, baseline scores, and a treatment-by-visit interaction term, using an unstructured covariance matrix for within-patient correlation. To preserve the type I error rate, a sequential testing procedure was employed, with the primary efficacy variable (change in PANSS total score for lurasidone 20 mg/d vs placebo) tested first. Interpretation of the result for the key secondary variable (CGI-S for lurasidone 20 mg/d vs placebo) could be made only if the result for the primary variable was significant. There were no adjustments for multiplicity for other secondary efficacy analyses.

The proportion of responders at study endpoint (defined as $\geq 20\%$ or $\geq 30\%$ reduction from baseline PANSS total score [with 30 points subtracted from each score to account for the scale range]) was compared between the lurasidone

It is illegal to post this copyrighted PDF on any website.

Figure 1. Patient Disposition in a Double-Blind, Randomized, Placebo-Controlled Study of Lurasidone for Schizophrenia



and placebo groups using logistic regression with the last observation carried forward (LOCF). The number needed to treat (NNT) to attain 1 additional responder was derived for the lurasidone groups as follows: $NNT = 1/(\text{lurasidone responders} - \text{placebo responders})$.

The safety population included all patients who were randomly assigned and received at least 1 dose of study medication. For all patients, including early nonresponders re-randomized at week 2, safety data were summarized from study baseline through endpoint.

Sample size was determined based on 2-sample *t* tests and powered at 80%. One hundred fifty patients (75 patients for each of the placebo and lurasidone 20 mg/d arms) were estimated to be required to detect an 8.8-point difference in mean change from baseline to week 6 in PANSS total score between lurasidone 20 mg/d and placebo (with a pooled standard deviation [SD] of 19). It was estimated that 92 patients (46 patients for each of the lurasidone ENR 80 mg/d and ENR 160 mg/d arms) were required to detect an 11.3-point treatment difference in mean change from week 2 to week 6 (with a pooled SD of 19). The total estimated sample size of 400 patients (placebo: 100 patients, lurasidone 20 mg/d: 100 patients, and lurasidone 80 mg/d: 200 patients) included an additional 86 patients based on expected attrition.

RESULTS

A total of 412 patients met all eligibility criteria and were randomly assigned to double-blind treatment with lurasidone 20 mg/d (*n* = 101), lurasidone 80 mg/d (*n* = 199),

or placebo (*n* = 112) (Figure 1). Demographic and clinical characteristics were similar for the 3 treatment groups randomized at study baseline (Table 1). After 2 weeks of treatment with lurasidone 80 mg/d, 98 patients (49.5%) were classified as early nonresponders (<20% improvement in PANSS total score) and re-randomized to continued treatment with lurasidone 80 mg/d (*n* = 55) or lurasidone 160 mg/d (*n* = 43).

Efficacy

In patients classified as early nonresponders at week 2, least squares (LS) mean change from week 2 to week 6 in PANSS total score was significantly greater for patients whose lurasidone dose was increased to 160 mg/d compared with that for patients who continued receiving 80 mg/d (-16.6 vs -8.9 [difference, 7.7]; $P < .05$ [effect size = 0.52]; Figure 2A). While a comparable magnitude of improvement was observed in CGI-S score from week 2 to week 6 for early nonresponders re-randomized to lurasidone 160 mg/d versus 80 mg/d (LS mean change, -1.0 vs -0.6 [difference, 0.4]; effect size = 0.44), the difference was not statistically significant ($P = .052$; Figure 2B). Treatment response (defined as $\geq 20\%$ decrease in PANSS total score from study baseline to week 6, LOCF) was demonstrated by 74.4% and 59.6% of early nonresponders re-randomized to lurasidone 160 mg/d and 80 mg/d, respectively ($P = .164$ [NNT, 7]); treatment response defined as $\geq 30\%$ PANSS total score decrease was demonstrated by 53.5% and 38.5% of patients, respectively ($P = .177$ [NNT, 7]). Results for other secondary efficacy outcomes in early nonresponders are reported in Supplementary eTable 1 (available at PSYCHIATRIST.COM).

Table 1. Demographic and Clinical Characteristics at Baseline of Patients in a Double-Blind, Randomized, Placebo-Controlled Study of Lurasidone for Schizophrenia (Intent-To-Treat Population)

Characteristic	Placebo (n = 112)		Lurasidone 20 mg/d (n = 101)		Lurasidone Randomized to 80 mg/d at Baseline (n = 198)		ER and ENR					
	n	%	n	%	n	%	ER 80 mg/d (n = 100)		ENR 80 mg/d (n = 52)		ENR 160 mg/d (n = 43)	
							n	%	n	%	n	%
Female	34	30.4	36	35.6	79	39.9	29	29.0	22	42.3	27	62.8
Race												
White	81	72.3	73	72.3	145	73.2	75	75.0	36	69.2	32	74.4
Black	24	21.4	21	20.8	42	21.2	22	22.0	12	23.1	7	16.3
Asian	1	0.9	1	1.0	2	1.0	0	0	1	1.9	1	2.3
Other	6	5.4	6	5.9	9	4.5	3	3.0	3	5.8	3	7.0
Hispanic/Latino ethnicity	10	8.9	8	7.9	14	7.1	7	7.0	3	5.8	4	9.3
≥ 4 previous hospitalizations	80	71.4	78	77.2	137	69.2	62	62.0	39	70.9	36	83.7
	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD	Mean	SD
Age, y	40.7	11.6	41.5	11.0	40.5	11.4	39.2	12.5	42.0	10.9	41.3	9.1
Age at onset of illness, y	26.5	9.0	26.6	9.7	26.4	9.3	25.8	10.0	27.3	9.4	26.6	7.2
Assessment scores												
PANSS	97.8	10.3	96.7	10.3	96.7	9.7	97.3	9.9	96.3	9.4	96.0	9.6
CGI-S	4.9	0.6	4.9	0.6	4.9	0.6	4.9	0.6	4.9	0.5	5.0	0.6

Abbreviations: CGI-S=Clinical Global Impression-Severity, ENR=early nonresponder, ER=early responder, PANSS=Positive and Negative Syndrome Scale, SD=standard deviation.

In patients receiving lurasidone 20 mg/d, LS mean change from baseline to week 6 in PANSS total score (the primary study endpoint, MMRM analysis) was not significantly different compared with patients receiving placebo (−17.6 vs −14.5; $P = .26$ [effect size = 0.19]). Similarly, LS mean change on the CGI-S was not significantly different in patients receiving lurasidone 20 mg/d compared with placebo (−0.9 vs −0.7; $P = .17$ [effect size = 0.22]). Patients initially randomized to lurasidone 80 mg/d demonstrated significant improvement overall compared with the placebo group at week 6 on both the PANSS (LS mean change, −24.9; $P < .001$ [effect size = 0.63]) and CGI-S (LS mean change, −1.3; $P < .001$ [effect size = 0.64]) scores (Figure 3A and 3B). These findings supported the assay sensitivity of the study.

Pharmacokinetic analysis evaluated the relationship between lurasidone exposure and early response/nonresponse (eAppendix 1).

Safety

Adverse events with incidence $\geq 5\%$ from study baseline to endpoint are listed in Table 2 for the following groups: lurasidone 20 mg/d, early nonresponders re-randomized to lurasidone 80 mg/d, and early nonresponders re-randomized to lurasidone 160 mg/d. Serious treatment-emergent adverse events were reported in 3 patients in the lurasidone 20 mg/d group, 4 patients in the early nonresponder 80 mg/d group, 1 patient in the early nonresponder 160 mg/d group, and 8 patients in the placebo group. No deaths occurred during the study. In early nonresponders, patients whose dose was increased to lurasidone 160 mg/d reported a greater incidence of anxiety, abdominal discomfort, akathisia, insomnia, and somnolence compared with patients who continued on lurasidone 80 mg/d (Table 2). The adverse

event profile was similar for early responders to lurasidone 80 mg/d (Supplementary eTable 2) and early nonresponders continued on lurasidone 80 mg/d, except for akathisia (16.0% vs 3.6%) and parkinsonism (5.0% vs 0.0%), which were more common in early responders. Adverse events with onset after re-randomization of early nonresponders at week 2 are shown in Supplementary eTable 3.

The proportion of patients with treatment-emergent suicidal ideation, per the C-SSRS, was 2.0% in the lurasidone 20 mg/d group, 3.6% in the early nonresponder 80 mg/d group, 4.7% in the early nonresponder 160 mg/d group, and 0% in the placebo group. There were no suicidal behavior reports or completed suicides during the study.


The incidence of extrapyramidal symptom-related adverse events is reported in Table 2. The proportion of patients who received anticholinergic medication at any time during treatment with study medication was 5.0% in the lurasidone 20 mg/d group, 9.0% in the early nonresponder 80 mg/d group, 9.3% in the early nonresponder 160 mg/d group, and 4.5% in the placebo group. LS mean change from baseline to LOCF endpoint in Simpson-Angus Scale, Barnes Akathisia Scale, and Abnormal Involuntary Movement Scale scores was small and not clinically meaningful in all treatment groups.

There were no clinically meaningful differences in the effect of treatment on laboratory parameters or vital signs (Table 3) or on ECG assessments between the lurasidone groups and the placebo group. Minimal changes in weight were observed across all groups, with no significant differences for the lurasidone groups (20 mg/d and 80 mg/d at initial randomization) compared with placebo. No patients in any lurasidone group had a postbaseline change in QTc Fridericia > 60 ms or a postbaseline QTc


It is illegal to post this copyrighted PDF on any website.

Figure 2. Change From Baseline Through Week 6 in Key Efficacy Measures in Early Nonresponders to Lurasidone 80 mg/d^a

A. PANSS Total Score



B. CGI-S Score



^aWeek 6 effect sizes for lurasidone 160 mg/d versus 80 mg/d: 0.52 on the PANSS and 0.44 on the CGI-S.

* $P < .05$ vs 80 mg/d.

** $P = .052$ vs 80 mg/d.

Abbreviations: CGI-S = Clinical Global Impression-Severity, PANSS = Positive and Negative Syndrome Scale.

Fridericia > 500 ms. Vital signs, laboratory tests, and ECG assessments were generally similar for early responders and early nonresponders to lurasidone 80 mg/d (Supplementary eTable 2).


DISCUSSION

This study utilized a rigorous, placebo-controlled design to evaluate the effect of dose escalation in adult patients with schizophrenia who demonstrated an inadequate initial response to lurasidone. The results reported here support

the safety and efficacy of dose escalation as a strategy for addressing early nonresponse to a standard dose of lurasidone in patients with schizophrenia. Dose increase to lurasidone 160 mg/d was associated with statistically significant and clinically meaningful improvement in symptoms of schizophrenia, as assessed by the PANSS total score, compared with continuation of the initial dose in early nonresponders to lurasidone 80 mg/d ($P < .05$; week 6 effect size = 0.52). In addition, clinically meaningful but statistically nonsignificant improvement was observed on the CGI-S ($P = .052$; week 6 effect size = 0.44).

It is illegal to post this copyrighted PDF on any website.

Figure 3. Change From Baseline Through Week 6 in Key Efficacy Measures in the Overall Intent-To-Treat Population^a



^aWeek 6 effect sizes for lurasidone 80–160 mg/d versus placebo: 0.63 on the PANSS and 0.64 on the CGI-S.
^bMean scores at baseline were 96.7 (SD = 10.3), 96.7 (SD = 9.7), and 97.8 (SD = 10.3) for the lurasidone 20 mg/d, lurasidone 80–160 mg/d, and placebo groups, respectively.
^cAll patients randomized to lurasidone 80 mg/d at study baseline with nonresponders re-randomized at week 2 to either 80 mg/d or 160 mg/d.
^dMean scores at baseline were 4.9 (SD = 0.6) for the lurasidone 20 mg/d, lurasidone 80–160 mg/d, and placebo groups.
 *P < .05 vs placebo.
 ***P < .01 vs placebo.
 ****P < .001 vs placebo.
 Abbreviations: CGI-S = Clinical Global Impression-Severity, PANSS = Positive and Negative Syndrome Scale, SD = standard deviation.

Early nonresponse to antipsychotic therapy in patients with schizophrenia has been identified as a robust predictor of poor response at short-term trial endpoints.¹ In this study, response/nonresponse was assessed after 2 weeks of treatment based on converging evidence from schizophrenia studies that evaluated receiver operating characteristics (eg, sensitivity, specificity, and positive and negative predictive values) and found that a 2-week decision time point may be ideal for prediction of short-term outcomes.^{2,6–9}

PANSS total score reduction < 20% was utilized to define nonresponse in this study. This change in PANSS total score is comparable to a rating of minimally improved or worse on the CGI-Improvement scale²⁰ and consistent with response thresholds utilized in previous research.^{4,7,21,22} Using this threshold of response, the present study showed that increasing the lurasidone dose to 160 mg/d at week 2 in nonresponders to lurasidone 80 mg/d was associated with a week 6 response rate of 74.4% compared with 59.6% for

It is illegal to post this copyrighted PDF on any website.

It is illegal to post this copyrighted PDF on any website.

patients who continued the 80 mg/d dose. The placebo-adjusted difference in response rates (or treatment effect size) for lurasidone 160 mg/d versus 80 mg/d was essentially unchanged when the response threshold was increased to a $\geq 30\%$ decrease from baseline PANSS total score (14.8%, NNT = 7 vs 15.0%, NNT = 7), suggesting that this finding was not dependent on PANSS response threshold. Increasing the lurasidone dose from 80 mg/d to 160 mg/d was associated with modest increases in the incidence of anxiety, abdominal discomfort, akathisia, insomnia, and somnolence, relative to continuing lurasidone 80 mg/d. Consistent with previous studies,^{23,24} short-term treatment with lurasidone in this study showed no clinically meaningful effects on weight, lipid parameters, and glucose levels.

We note that an appreciable proportion of patients classified as nonresponders at week 2 in this study went on to demonstrate response after 6 weeks of treatment in

the absence of dose escalation (ie, on lurasidone 80 mg/d). Therefore, the increased probability of response in early nonresponders after dose escalation to lurasidone 160 mg/d should be considered in the context of the risk-versus-benefit findings associated with this strategy. These considerations include a modest increase in the frequency of certain adverse events and the clinical need to enhance the rate of response.

Study designs for evaluating the effectiveness of dose escalation in early nonresponding patients with schizophrenia have been proposed by Correll et al.²⁵ However, few randomized, controlled studies have evaluated dose escalation as a strategy for addressing early nonresponse to antipsychotic therapy. A recent meta-analysis²⁶ included 5 trials (348 patients) investigating dose escalation with quetiapine (2 studies), ziprasidone, haloperidol, or fluphenazine. There was no evidence that patients with early nonresponse benefited from dose escalation; no significant differences were found in mean PANSS/Brief Psychiatric Rating Scale score change between the dose-increase and control groups, and the pooled effect size for the primary outcome was 0.14.²⁶ Sample sizes were relatively small, however, and nonresponse was assessed after 3 or 4 weeks of treatment in most studies. None of the 5 studies included a placebo-only treatment arm, and the 3 more recent studies that tested dose escalation of quetiapine and ziprasidone examined suprathreshold doses that exceeded the maximum recommended limit contained in product labeling.

In contrast to prior studies, dose escalation was found to be efficacious in this study of patients with schizophrenia treated with lurasidone. Several factors may have contributed to the ability to detect an effect of lurasidone dose escalation in this study. First, inclusion of a placebo-control group may have reduced expectation bias toward improvement on the part of both patients and investigators, thereby enhancing signal detection in this study. Second, it is possible that D₂ receptor occupancy was more optimal in early nonresponders treated with lurasidone 160 mg/d compared with 80 mg/d. Imaging studies have shown a strong relationship between serum lurasidone concentration and D₂ receptor occupancy.^{27,28} A PET study of patients with

Table 2. Adverse Events Occurring From Study Baseline to Week 6 Endpoint (Incidence $\geq 5\%$ in the Lurasidone 20 mg/d, Early Nonresponder 80 mg/d, or Early Nonresponder 160 mg/d Groups; Safety Population)

Adverse Event	Placebo (n=112)		Lurasidone 20 mg/d (n=101)		ENR 80 mg/d (n=55)		ENR 160 mg/d (n=43)	
	n	%	n	%	n	%	n	%
≥ 1 event	72	64.3	55	54.5	34	61.8	29	67.4
Insomnia	24	21.4	16	15.8	5	9.1	5	11.6
Headache	8	7.1	10	9.9	4	7.3	3	7.0
Anxiety	7	6.3	8	7.9	0	0	4	9.3
Agitation	11	9.8	5	5.0	4	7.3	2	4.7
Akathisia	2	1.8	5	5.0	2	3.6	3	7.0
Nausea	4	3.6	2	2.0	6	10.9	2	4.7
Somnolence	6	5.4	5	5.0	2	3.6	2	4.7
Sedation	2	1.8	3	3.0	3	5.5	1	2.3
Tremor	2	1.8	2	2.0	3	5.5	1	2.3
Vomiting	1	0.9	0	0	3	5.5	2	4.7
Restlessness	4	3.6	0	0	3	5.5	1	2.3
Abdominal discomfort	1	0.9	1	1.0	0	0	3	7.0
Extrapyramidal events ^a	5	4.5	4	4.0	5	9.1	2	4.7

^aCombination term that included any of the following: cogwheel rigidity, drooling, dystonia, glabellar reflex abnormal, muscle rigidity, parkinsonism, torticollis, tremor, and trismus.
Abbreviation: ENR=early nonresponder.

Table 3. Baseline to Endpoint Change in Weight and Laboratory Parameters (Last Observation Carried Forward)^a

Measure	Placebo (n=112)			Lurasidone 20 mg/d (n=101)			ENR 80 mg/d (n=55)			ENR 160 mg/d (n=43)		
	Mean	SD	Median	Mean	SD	Median	Mean	SD	Median	Mean	SD	Median
Weight, kg ^b	0.1	2.5	0.1	0.5	2.4	0.5	0.1	2.7	0.0	0.5	2.1	0.4
Waist circumference, cm	0.1	3.1	0.0	0.4	2.6	0.0	-0.5	2.6	0.0	0.1	4.5	0.0
Total cholesterol, mg/dL	3.1	31.5	4.0	-4.3	30.8	-3.0	-1.9	31.3	0.0	5.0	30.3	7.0
LDL cholesterol, mg/dL	7.0	26.0	9.0	-0.8	24.7	-1.0	2.4	27.9	0.0	3.6	24.0	-1.0
Triglycerides, mg/dL	-14.2	66.5	-8.5	-7.5	68.9	-3.0	-18.5	80.6	-19.5	-2.5	81.8	-3.0
Glucose, mg/dL	5.1	20.9	1.0	-0.2	21.1	-2.0	-0.3	19.3	-1.0	0.8	13.6	-1.0
Prolactin, ng/mL												
Men	-5.6	14.2	-1.3	-5.5	15.5	-1.1	-3.0	10.4	0.4	-2.1	21.4	4.0
Women	-2.1	57.0	-1.7	-13.2	37.2	-1.9	-13.2	30.4	-5.4	-9.6	40.7	2.4

^aBoth confirmed and nonconfirmed fasting values are presented for metabolic parameters.

^bThe proportions of patients with $\geq 7\%$ increase in weight at endpoint were 2.2% in the lurasidone 20 mg/d group, 3.8% in the early nonresponder 80 mg/d group, 2.4% in the early nonresponder 160 mg/d group, and 2.8% in the placebo group.

Abbreviations: ENR=early nonresponder, LDL=low-density lipoprotein, SD=standard deviation.

It is illegal to post this copyrighted PDF on any website.

schizophrenia randomly assigned to receive lurasidone 80, 120, or 160 mg/d for 1 week indicated that doses greater than 80 mg/d may be necessary to achieve therapeutic threshold levels of D₂ receptor occupancy in some patients.²⁸ In support of these observations, in this study, serum lurasidone concentration increased in a dose-related fashion, with an approximately 2-fold increase observed in patients treated with lurasidone 160 mg/d compared with patients continued on 80 mg/d. Notably, serum lurasidone concentration in patients receiving lurasidone 80 mg/d did not differentiate treatment responders from nonresponders at week 2. Third, in a prior short-term, placebo-controlled, fixed-dose study in patients with schizophrenia, a significantly higher rate of response was observed in patients treated with lurasidone 160 mg/d compared with 80 mg/d.^{18,29} The observed effects of lurasidone dose escalation in the current study are therefore consistent with previous observations of dose-response in association with lurasidone treatment.³⁰

In this study, lurasidone 20 mg/d was not found to be efficacious in the treatment of patients with an acute exacerbation of schizophrenia. In contrast, the patient group initially randomized to 80 mg/d showed substantial improvement on the PANSS and CGI-S compared with the placebo group (week 6 effect sizes of 0.63 and 0.64, respectively). Given the efficacy demonstrated in patients randomized to lurasidone 80 mg/d, it appears that the absence of significant improvement in psychotic symptoms associated with lurasidone 20 mg/d represents a true negative result (because an effect of treatment was demonstrated in the group exposed to standard-dose lurasidone) and not a failed study (in which known effective treatment[s] or

dose[s] fail to separate from placebo). This study, taken together with the findings from previous lurasidone efficacy trials, indicates that the lowest effective dose of lurasidone for the treatment of schizophrenia is 40 mg/d, as noted in current prescribing information.³¹

Several study limitations should be noted. The efficacy of dose escalation represented a secondary assessment in this study (the efficacy of lurasidone 20 mg/d was the primary endpoint). Treatment duration was relatively brief, and it is not known whether the differences between lurasidone 160 mg/d and 80 mg/d observed in this short-term study would be maintained beyond 4 weeks of treatment. The effect of increase to an intermediate lurasidone dose between 80 mg/d and 160 mg/d (ie, 120 mg/d) in patients with early nonresponse was not evaluated in this study. It is possible that determination of nonresponse at a different time point (particularly later than 2 weeks) may reduce observed differences between the lurasidone dose groups. Assessment of adverse effect frequencies associated with standard versus high lurasidone dose was limited due to relatively small sample sizes and number of adverse event reports.

In this study, dose increase of lurasidone in early nonresponders resulted in superior efficacy compared with continuing the initial dose, with modest increases in the incidence of some adverse events. Lurasidone 20 mg/d was not found to be an efficacious treatment for patients with schizophrenia, supporting the currently recommended lurasidone dose range of 40–160 mg/d. Dose escalation may be a preferred treatment approach for patients with schizophrenia who demonstrate an inadequate initial response to lurasidone.

Submitted: January 21, 2016; accepted June 20, 2016.

Online first: July 19, 2016.

Drug names: lorazepam (Ativan and others), lurasidone (Latuda), propranolol (Inderal and others), quetiapine (Seroquel and others), temazepam (Restoril and others), ziprasidone (Geodon and others), zolpidem (Ambien, Edluar, and others).

Potential conflicts of interest: Drs Loebel, Silva, Goldman, and Cucchiari and Ms Watabe are employees of Sunovion Pharmaceuticals Inc. Dr Citrome has engaged in collaborative research with or received consulting or speaking fees from Acadia, Alexza, Alkermes, Allergan (Actavis, Forest), AstraZeneca, Avanir, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly and Company, Forum, Genentech, Intra-Cellular Therapies, Janssen, Jazz, Lundbeck, Medivation, Inc, Merck & Co, Inc, Mylan, Novartis, Noven, Otsuka, Pfizer, Reckitt Benckiser, Reviva, Shire, Sunovion, Takeda, Teva, Valeant, and Vanda. Dr Kane has been a consultant for Alkermes, Bristol-Myers Squibb, Eli Lilly, Forest, Forum, Genentech, Lundbeck, Intra-Cellular Therapies, Janssen, Johnson & Johnson, Novartis, Otsuka, Reviva, Roche, Sunovion, and Teva; has received honoraria from Alkermes, Bristol-Myers Squibb, Eli Lilly, Forest, Forum, Genentech, Lundbeck, Intra-Cellular Therapies, Janssen, Johnson & Johnson, Otsuka, Reviva, Roche, Sunovion, and Teva; has been on the speakers/advisory boards for Bristol-Myers Squibb, Genentech,

and Otsuka; and has been a stock shareholder in MedAvante.

Funding/support: This study was sponsored by Sunovion Pharmaceuticals Inc.

Role of the sponsor: The sponsor was involved in the study design, collection, and analysis of data. The interpretation of results and the decision to submit this manuscript for publication in *The Journal of Clinical Psychiatry* were made by the authors independently.

Previous presentations: Presented in part at the 53rd Annual Meeting of the American College of Neuropsychopharmacology, December 7–11, 2014, Phoenix, Arizona; 15th International Congress on Schizophrenia Research, March 28–April 1, 2015, Colorado Springs, Colorado; the 168th Annual Meeting of the American Psychiatric Association, May 16–20, 2015, Toronto, Canada; and the US Psychiatric and Mental Health Congress, September 10–13, 2015, San Diego, California.

Acknowledgments: The authors thank the study investigators for their participation and Michael Tocco, PhD, for scientific review of this article. Nancy Holland, PhD, Synchrony Medical Communications, LLC, provided medical writing and editorial assistance for this manuscript under the direction of the authors. Financial support for this writing and editorial assistance from Synchrony Medical Communications, LLC, was provided by Sunovion Pharmaceuticals Inc, Marlborough, Massachusetts. Clinical research was sponsored by Sunovion Pharmaceuticals Inc.

Supplementary material: Available at PSYCHIATRIST.COM.

REFERENCES

- Samara MT, Leucht C, Leeflang MM, et al. Early improvement as a predictor of later response to antipsychotics in schizophrenia: a diagnostic test review. *Am J Psychiatry*. 2015;172(7):617–629.
- O’Gorman C, Kapur S, Kolluri S, et al. Early improvement on antipsychotic treatment as a predictor of subsequent response in schizophrenia: analyses from ziprasidone clinical studies. *Hum Psychopharmacol*. 2011;26(4–5):282–290.
- Stauffer VL, Case M, Kinon BJ, et al. Early response to antipsychotic therapy as a clinical marker of subsequent response in the treatment of patients with first-episode psychosis. *Psychiatry Res*. 2011;187(1–2):42–48.
- Kinon BJ, Chen L, Ascher-Svanum H, et al. Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia. *Neuropsychopharmacology*. 2010;35(2):581–590.
- Kinon BJ, Chen L, Stauffer VL, et al. Early onset of antipsychotic action in schizophrenia: evaluating the possibility of shorter acute efficacy trials. *J Clin Psychopharmacol*. 2010;30(3):286–289.
- Ascher-Svanum H, Nyhuis AW, Faries DE, et al. Clinical, functional, and economic

It is illegal to post this copyrighted PDF on any website.

- ramifications of early nonresponse to antipsychotics in the naturalistic treatment of schizophrenia. *Schizophr Bull.* 2008;34(6):1163–1171.
7. Kinon BJ, Chen L, Ascher-Svanum H, et al. Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia. *Schizophr Res.* 2008;102(1–3):230–240.
 8. Leucht S, Busch R, Kissling W, et al. Early prediction of antipsychotic nonresponse among patients with schizophrenia. *J Clin Psychiatry.* 2007;68(3):352–360.
 9. Chang YC, Lane HY, Yang KH, et al. Optimizing early prediction for antipsychotic response in schizophrenia. *J Clin Psychopharmacol.* 2006;26(6):554–559.
 10. Correll CU, Malhotra AK, Kaushik S, et al. Early prediction of antipsychotic response in schizophrenia. *Am J Psychiatry.* 2003;160(11):2063–2065.
 11. Hatta K, Ito H. Strategies for early non-response to antipsychotic drugs in the treatment of acute-phase schizophrenia. *Clin Psychopharmacol Neurosci.* 2014;12(1):1–7.
 12. Buckley PF, Correll CU. Strategies for dosing and switching antipsychotics for optimal clinical management. *J Clin Psychiatry.* 2008;69(suppl 1):4–17.
 13. Ishibashi T, Horisawa T, Tokuda K, et al. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT₇) and 5-HT_{1A} receptor activity. *J Pharmacol Exp Ther.* 2010;334(1):171–181.
 14. Ogasa M, Kimura T, Nakamura M, et al. Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study. *Psychopharmacology (Berl).* 2013;225(3):519–530.
 15. Nakamura M, Ogasa M, Guarino J, et al. Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial. *J Clin Psychiatry.* 2009;70(6):829–836.
 16. Meltzer HY, Cucchiaro J, Silva R, et al. Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study. *Am J Psychiatry.* 2011;168(9):957–967.
 17. Nasrallah HA, Silva R, Phillips D, et al. Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study. *J Psychiatr Res.* 2013;47(5):670–677.
 18. Loebel A, Cucchiaro J, Sarma K, et al. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial. *Schizophr Res.* 2013;145(1–3):101–109.
 19. Loebel A, Citrome L, Correll CU, et al. Treatment of early non-response in patients with schizophrenia: assessing the efficacy of antipsychotic dose escalation. *BMC Psychiatry.* 2015;15(1):271.
 20. Leucht S, Kane JM, Kissling W, et al. What does the PANSS mean? *Schizophr Res.* 2005;79(2–3):231–238.
 21. Liu-Seifert H, Adams DH, Kinon BJ. Discontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugs. *BMC Med.* 2005;3(1):21.
 22. Leucht S, Zhao J. Early improvement as a predictor of treatment response and remission in patients with schizophrenia: a pooled, post-hoc analysis from the asenapine development program. *J Psychopharmacol.* 2014;28(4):387–394.
 23. Citrome L. Lurasidone for the acute treatment of adults with schizophrenia: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed? *Clin Schizophr Relat Psychoses.* 2012;6(2):76–85.
 24. Citrome L. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic. *Int J Clin Pract.* 2011;65(2):189–210.
 25. Correll CU, Kishimoto T, Kane JM. Randomized controlled trials in schizophrenia: opportunities, limitations, and trial design alternatives. *Dialogues Clin Neurosci.* 2011;13(2):155–172.
 26. Dold M, Fugger G, Aigner M, et al. Dose escalation of antipsychotic drugs in schizophrenia: a meta-analysis of randomized controlled trials. *Schizophr Res.* 2015;166(1–3):187–193.
 27. Wong DF, Kuwabara H, Brašić JR, et al. Determination of dopamine D₂ receptor occupancy by lurasidone using positron emission tomography in healthy male subjects. *Psychopharmacology (Berl).* 2013;229(2):245–252.
 28. Potkin SG, Keator DB, Kesler-West ML, et al. D₂ receptor occupancy following lurasidone treatment in patients with schizophrenia or schizoaffective disorder. *CNS Spectr.* 2014;19(2):176–181.
 29. Loebel A, Cucchiaro J, Silva R, et al. Efficacy of lurasidone across five symptom dimensions of schizophrenia: pooled analysis of short-term, placebo-controlled studies. *Eur Psychiatry.* 2015;30(1):26–31.
 30. Chapel S, Chiu YY, Hsu J, et al. Lurasidone dose response in bipolar depression: a population dose-response analysis. *Clin Ther.* 2016;38(1):4–15.
 31. Latuda (lurasidone hydrochloride) tablets, for oral use [package insert]. Marlborough, MA: Sunovion Pharmaceuticals, Inc; 2013.

See supplementary material for this article at PSYCHIATRIST.COM.

It is illegal to post this copyrighted PDF on any website.



THE JOURNAL OF
CLINICAL PSYCHIATRY

THE OFFICIAL JOURNAL OF THE AMERICAN SOCIETY OF CLINICAL PSYCHOPHARMACOLOGY

Supplementary Material

Article Title: Lurasidone Dose Escalation in Early Nonresponding Patients With Schizophrenia: A Randomized, Placebo-Controlled Study

Author(s): Antony Loebel, MD; Robert Silva, PhD; Robert Goldman, PhD; Kei Watabe, MS; Josephine Cucchiaro, PhD; Leslie Citrome, MD, MPH; and John M. Kane, MD

DOI Number: 10.4088/JCP.16m10698

List of Supplementary Material for the article

1. [eAppendix 1](#) Pharmacokinetic Analysis
2. [eTable 1](#) Change From Week 2 to Week 6 on Secondary Efficacy Measures in Early Nonresponders Re-randomized at Week 2 to Lurasidone 80 mg/day or 160 mg/day (Intent-to-Treat Population; MMRM Analysis)
3. [eTable 2](#) Safety Assessments in Early Responders to Lurasidone 80 mg/day: Adverse Events Occurring From Study Baseline to Week 6 Endpoint in $\geq 5\%$ of Early Responders and Baseline to Endpoint Change in Weight, Laboratory Parameters, and ECG (Last Observation Carried Forward)
4. [eTable 3](#) Adverse Events With Onset After Week 2 (Incidence $\geq 3\%$ in Early Nonresponders Re-randomized at Week 2 to Lurasidone 80 mg/day or 160 mg/day; Safety Population)

Disclaimer

This Supplementary Material has been provided by the author(s) as an enhancement to the published article. It has been approved by peer review; however, it has undergone neither editing nor formatting by in-house editorial staff. The material is presented in the manner supplied by the author.

eAppendix 1

Pharmacokinetic Analysis

Pharmacokinetic analysis was conducted to evaluate the relationship between lurasidone exposure and early response/nonresponse. Mean (SD) trough serum concentration of lurasidone at week 2 was 8.2 (5.3) ng/mL in early responders (n = 55) and 10.3 (8.9) ng/mL in early nonresponders (n = 71) to lurasidone 80 mg/day. At week 6, mean (SD) serum concentration at 14–15 hours postdose was 13.3 (10.2) ng/mL in early responders (n = 18), 14.7 (12.3) ng/mL in early nonresponders continued on lurasidone 80 mg/day (n = 15), and 29.1 (18.5) ng/mL in early nonresponders with dose increased to 160 mg/day (n = 11).

Supplementary eTable 1. Change From Week 2 to Week 6 on Secondary Efficacy Measures in Early Nonresponders Re-randomized at Week 2 to Lurasidone 80 mg/day or 160 mg/day (Intent-to-Treat Population; MMRM Analysis)

Outcome Measure	Early Nonresponders Lurasidone 80 mg/d (n = 52)		Early Nonresponders Lurasidone 160 mg/d (n = 43)	
	LS mean	SE	LS mean	SE
PANSS positive	-3.2	0.6	-5.2*	0.7
PANSS negative	-2.1	0.6	-3.0	0.7
PANSS general psychopathology	-4.0	1.1	-8.6**	1.3
PANSS excitability	-0.9	0.5	-3.4**	0.6
PANSS depression	-1.2	0.3	-2.1*	0.4

* $P < .05$ versus ENR 80 mg/day.

** $P < .01$ versus ENR 80 mg/day.

Abbreviations: ENR = early nonresponder; LS = least squares; PANSS = Positive and Negative Syndrome Scale; SE = standard error.

Supplementary eTable 2. Safety Assessments in Early Responders to Lurasidone 80 mg/day: Adverse Events Occurring From Study Baseline to Week 6 Endpoint in $\geq 5\%$ of Early Responders^a and Baseline to Endpoint Change in Weight, Laboratory Parameters, and ECG (Last Observation Carried Forward)^b

Early Responders Lurasidone						
80 mg/d (n = 100)						
Adverse Events			Weight and Laboratory Parameters			
	N	%		Mean	SD	Median
≥ 1 event	58	58.0	Weight (kg) ^c	0.5	1.9	0.5
Akathisia	16	16.0	Waist circumference (cm)	0.1	2.5	0.0
Insomnia	11	11.0	Total cholesterol (mg/dL)	1.3	28.7	-1.0
Nausea	9	9.0	LDL cholesterol (mg/dL)	0.1	22.7	2.0
Vomiting	6	6.0	Triglycerides (mg/dL)	4.4	72.4	-5.0
Diarrhea	5	5.0	Glucose (mg/dL)	-0.5	15.3	-2.0
	5	5.0	Prolactin (ng/mL)			
Parkinsonism			Men	-5.7	12.0	-2.2
			Women	5.6	46.4	-0.5
Extrapyramidal events ^{d,e}	8	8.0	QTcF (ms)	-1.4	18.2	0.0

^aSuicidal ideation (assessed using the Columbia Suicide Severity Rating Scale) was noted in 1 patient (1.0%).

^bBoth confirmed and nonconfirmed fasting values are presented for metabolic parameters.

^cWeight gain $\geq 7\%$ was observed in 3.5% of patients.

^dCombination term that included any of the following: cogwheel rigidity, drooling, dystonia, glabellar reflex abnormal, muscle rigidity, parkinsonism, torticollis, tremor, and trismus.

^eAnticholinergic medication was used in 15.0% of patients.

Abbreviations: LDL = low-density lipoprotein; QTcF = heart rate–corrected QT interval,

Fridericia's formula; SD = standard deviation.

Supplementary eTable 3. Adverse Events With Onset After Week 2 (Incidence $\geq 3\%$ in Early Nonresponders Re-randomized at Week 2 to Lurasidone 80 mg/day or 160 mg/day; Safety Population)

Adverse Event	Early Nonresponders Lurasidone 80 mg/d (n = 55)		Early Nonresponders Lurasidone 160 mg/d (n = 43)	
	N	%	N	%
≥ 1 event	21	38.2	23	53.5
Insomnia	3	5.5	3	7.0
Akathisia	2	3.6	2	4.7
Anxiety	0	0	3	7.0
Abdominal discomfort	0	0	2	4.7
Nausea	2	3.6	1	2.3
Vomiting	2	3.6	1	2.3
Schizophrenia	2	3.6	1	2.3
Headache	3	5.5	0	0
Psychotic disorder	2	3.6	0	0
Respiratory tract infection (viral)	2	3.6	0	0
Suicidal ideation	2	3.6	0	0